ASX - By Stock
|
RCE |
Re:
Ann: Recce Completes 5,000 R327 Doses Per Week under GMP
|
|
BelowAverage
|
44 |
15K |
4 |
21/04/24 |
21/04/24 |
ASX - By Stock
|
44
|
15K
|
4
|
|
ASX - By Stock
|
GGE |
Re:
Ann: Deeper Stacked Helium Pay Adds Scale to Red Helium Project
|
|
BelowAverage
|
14 |
3.8K |
0 |
17/04/24 |
17/04/24 |
ASX - By Stock
|
14
|
3.8K
|
0
|
|
ASX - By Stock
|
RCE |
Re:
Ann: Application for quotation of securities - RCE
|
|
BelowAverage
|
2 |
883 |
1 |
17/04/24 |
17/04/24 |
ASX - By Stock
|
2
|
883
|
1
|
|
ASX - By Stock
|
RCE |
Re:
Ann: Recce Completes 5,000 R327 Doses Per Week under GMP
|
|
BelowAverage
|
44 |
15K |
2 |
17/04/24 |
17/04/24 |
ASX - By Stock
|
44
|
15K
|
2
|
|
ASX - By Stock
|
RCE |
Re:
Ann: Recce Completes 5,000 R327 Doses Per Week under GMP
|
|
BelowAverage
|
44 |
15K |
5 |
16/04/24 |
16/04/24 |
ASX - By Stock
|
44
|
15K
|
5
|
|
ASX - By Stock
|
GGE |
Re:
Ann: Deeper Stacked Helium Pay Adds Scale to Red Helium Project
|
|
BelowAverage
|
14 |
3.8K |
4 |
16/04/24 |
16/04/24 |
ASX - By Stock
|
14
|
3.8K
|
4
|
|
ASX - By Stock
|
RCE |
Re:
[INTERVIEW] Recce gearing up for Indonesian trials
|
|
BelowAverage
|
36 |
9.8K |
2 |
15/04/24 |
15/04/24 |
ASX - By Stock
|
36
|
9.8K
|
2
|
|
ASX - By Stock
|
GGE |
Re:
Price prediction
|
|
BelowAverage
|
50 |
18K |
0 |
14/04/24 |
14/04/24 |
ASX - By Stock
|
50
|
18K
|
0
|
|
ASX - By Stock
|
RCE |
Re:
Ann: Recce Pharmaceuticals - Business Update
|
|
BelowAverage
|
22 |
7.8K |
6 |
10/04/24 |
10/04/24 |
ASX - By Stock
|
22
|
7.8K
|
6
|
|
ASX - By Stock
|
RCE |
Re:
Ann: Recce Pharmaceuticals - Business Update
|
|
BelowAverage
|
22 |
7.8K |
0 |
09/04/24 |
09/04/24 |
ASX - By Stock
|
22
|
7.8K
|
0
|
|
ASX - By Stock
|
RCE |
Re:
Ann: Recce Pharmaceuticals - Business Update
|
|
BelowAverage
|
22 |
7.8K |
6 |
08/04/24 |
08/04/24 |
ASX - By Stock
|
22
|
7.8K
|
6
|
|
ASX - By Stock
|
RCE |
Re:
Ann: Recce Pharmaceuticals - Business Update
|
|
BelowAverage
|
22 |
7.8K |
9 |
08/04/24 |
08/04/24 |
ASX - By Stock
|
22
|
7.8K
|
9
|
|
ASX - By Stock
|
RCE |
Re:
Ann: Cohort Dosing Complete Ph I/II UTI/Urosepsis Clinical Trial
|
|
BelowAverage
|
48 |
14K |
1 |
29/03/24 |
29/03/24 |
ASX - By Stock
|
48
|
14K
|
1
|
|
ASX - By Stock
|
RCE |
Re:
Ann: Cohort Dosing Complete Ph I/II UTI/Urosepsis Clinical Trial
|
|
BelowAverage
|
48 |
14K |
2 |
28/03/24 |
28/03/24 |
ASX - By Stock
|
48
|
14K
|
2
|
|
ASX - By Stock
|
RCE |
Re:
Ann: Cohort Dosing Complete Ph I/II UTI/Urosepsis Clinical Trial
|
|
BelowAverage
|
48 |
14K |
2 |
27/03/24 |
27/03/24 |
ASX - By Stock
|
48
|
14K
|
2
|
|
ASX - By Stock
|
RCE |
Re:
Ann: Cohort Dosing Complete Ph I/II UTI/Urosepsis Clinical Trial
|
|
BelowAverage
|
48 |
14K |
1 |
24/03/24 |
24/03/24 |
ASX - By Stock
|
48
|
14K
|
1
|
|
ASX - By Stock
|
RCE |
Re:
Ann: Cohort Dosing Complete Ph I/II UTI/Urosepsis Clinical Trial
|
|
BelowAverage
|
48 |
14K |
3 |
23/03/24 |
23/03/24 |
ASX - By Stock
|
48
|
14K
|
3
|
|
ASX - By Stock
|
RCE |
Re:
Ann: Cohort Dosing Complete Ph I/II UTI/Urosepsis Clinical Trial
|
|
BelowAverage
|
48 |
14K |
4 |
19/03/24 |
19/03/24 |
ASX - By Stock
|
48
|
14K
|
4
|
|
ASX - By Stock
|
GGE |
Re:
Price prediction
|
|
BelowAverage
|
50 |
18K |
1 |
17/03/24 |
17/03/24 |
ASX - By Stock
|
50
|
18K
|
1
|
|
ASX - By Stock
|
GGE |
Re:
Price prediction
|
|
BelowAverage
|
50 |
18K |
0 |
16/03/24 |
16/03/24 |
ASX - By Stock
|
50
|
18K
|
0
|
|
ASX - By Stock
|
RCE |
Re:
Ann: Cohort Dosing Complete Ph I/II UTI/Urosepsis Clinical Trial
|
|
BelowAverage
|
48 |
14K |
0 |
15/03/24 |
15/03/24 |
ASX - By Stock
|
48
|
14K
|
0
|
|
ASX - By Stock
|
RCE |
Re:
Ann: Next Cohort Dosing Ph I/II UTI/Urosepsis Clinical Trial
|
|
BelowAverage
|
39 |
8.3K |
2 |
14/03/24 |
14/03/24 |
ASX - By Stock
|
39
|
8.3K
|
2
|
|
ASX - By Stock
|
RCE |
Re:
Ann: Recce Receives AUD $11.17m R&D Advance
|
|
BelowAverage
|
38 |
10K |
3 |
14/03/24 |
14/03/24 |
ASX - By Stock
|
38
|
10K
|
3
|
|
ASX - By Stock
|
RCE |
Re:
Ann: Recce Receives AUD $11.17m R&D Advance
|
|
BelowAverage
|
38 |
10K |
1 |
14/03/24 |
14/03/24 |
ASX - By Stock
|
38
|
10K
|
1
|
|
ASX - By Stock
|
RCE |
Re:
Ann: Next Cohort Dosing Ph I/II UTI/Urosepsis Clinical Trial
|
|
BelowAverage
|
39 |
8.3K |
4 |
14/03/24 |
14/03/24 |
ASX - By Stock
|
39
|
8.3K
|
4
|
|
ASX - By Stock
|
RCE |
Re:
Ann: Next Cohort Dosing Ph I/II UTI/Urosepsis Clinical Trial
|
|
BelowAverage
|
39 |
8.3K |
9 |
13/03/24 |
13/03/24 |
ASX - By Stock
|
39
|
8.3K
|
9
|
|
ASX - By Stock
|
RCE |
Re:
Ann: Next Cohort Dosing Ph I/II UTI/Urosepsis Clinical Trial
|
|
BelowAverage
|
39 |
8.3K |
2 |
13/03/24 |
13/03/24 |
ASX - By Stock
|
39
|
8.3K
|
2
|
|
ASX - By Stock
|
RCE |
Re:
Ann: Recce Receives AUD $11.17m R&D Advance
|
|
BelowAverage
|
38 |
10K |
3 |
13/03/24 |
13/03/24 |
ASX - By Stock
|
38
|
10K
|
3
|
|
ASX - By Stock
|
RCE |
Re:
Ann: Next Cohort Dosing Ph I/II UTI/Urosepsis Clinical Trial
|
|
BelowAverage
|
39 |
8.3K |
0 |
13/03/24 |
13/03/24 |
ASX - By Stock
|
39
|
8.3K
|
0
|
|
ASX - By Stock
|
RCE |
Re:
Ann: Next Cohort Dosing Ph I/II UTI/Urosepsis Clinical Trial
|
|
BelowAverage
|
39 |
8.3K |
3 |
13/03/24 |
13/03/24 |
ASX - By Stock
|
39
|
8.3K
|
3
|
|
ASX - By Stock
|
GGE |
Re:
Price prediction
|
|
BelowAverage
|
50 |
18K |
0 |
12/03/24 |
12/03/24 |
ASX - By Stock
|
50
|
18K
|
0
|
|
ASX - By Stock
|
RCE |
Re:
Ann: Next Cohort Dosing Ph I/II UTI/Urosepsis Clinical Trial
|
|
BelowAverage
|
39 |
8.3K |
4 |
12/03/24 |
12/03/24 |
ASX - By Stock
|
39
|
8.3K
|
4
|
|
ASX - By Stock
|
RCE |
Re:
Ann: Next Cohort Dosing Ph I/II UTI/Urosepsis Clinical Trial
|
|
BelowAverage
|
39 |
8.3K |
6 |
12/03/24 |
12/03/24 |
ASX - By Stock
|
39
|
8.3K
|
6
|
|
ASX - By Stock
|
RCE |
Re:
Ann: Next Cohort Dosing Ph I/II UTI/Urosepsis Clinical Trial
|
|
BelowAverage
|
39 |
8.3K |
2 |
12/03/24 |
12/03/24 |
ASX - By Stock
|
39
|
8.3K
|
2
|
|
ASX - By Stock
|
RCE |
Re:
Ann: Next Cohort Dosing Ph I/II UTI/Urosepsis Clinical Trial
|
|
BelowAverage
|
39 |
8.3K |
2 |
12/03/24 |
12/03/24 |
ASX - By Stock
|
39
|
8.3K
|
2
|
|
ASX - By Stock
|
RCE |
Re:
Ann: Recce Receives AUD $11.17m R&D Advance
|
|
BelowAverage
|
38 |
10K |
5 |
12/03/24 |
12/03/24 |
ASX - By Stock
|
38
|
10K
|
5
|
|
ASX - By Stock
|
RCE |
Re:
Ann: Recce Receives AUD $11.17m R&D Advance
|
|
BelowAverage
|
38 |
10K |
1 |
11/03/24 |
11/03/24 |
ASX - By Stock
|
38
|
10K
|
1
|
|
ASX - By Stock
|
RCE |
Re:
Ann: Recce Receives AUD $11.17m R&D Advance
|
|
BelowAverage
|
38 |
10K |
2 |
11/03/24 |
11/03/24 |
ASX - By Stock
|
38
|
10K
|
2
|
|
ASX - By Stock
|
RCE |
Re:
Ann: Recce Receives AUD $11.17m R&D Advance
|
|
BelowAverage
|
38 |
10K |
3 |
11/03/24 |
11/03/24 |
ASX - By Stock
|
38
|
10K
|
3
|
|
ASX - By Stock
|
RCE |
Re:
Ann: Recce Receives AUD $11.17m R&D Advance
|
|
BelowAverage
|
38 |
10K |
2 |
11/03/24 |
11/03/24 |
ASX - By Stock
|
38
|
10K
|
2
|
|
ASX - By Stock
|
FHE |
Re:
Ann: DFS Presentation
|
|
BelowAverage
|
17 |
4.8K |
2 |
10/03/24 |
10/03/24 |
ASX - By Stock
|
17
|
4.8K
|
2
|
|
ASX - By Stock
|
RCE |
Re:
Ann: Recce Receives AUD $11.17m R&D Advance
|
|
BelowAverage
|
38 |
10K |
3 |
08/03/24 |
08/03/24 |
ASX - By Stock
|
38
|
10K
|
3
|
|
ASX - By Stock
|
RCE |
Re:
Ann: Recce Continues Strategic Partnership with MCRI
|
|
BelowAverage
|
53 |
14K |
5 |
06/03/24 |
06/03/24 |
ASX - By Stock
|
53
|
14K
|
5
|
|
ASX - By Stock
|
RCE |
Re:
Ann: Recce Continues Strategic Partnership with MCRI
|
|
BelowAverage
|
53 |
14K |
0 |
05/03/24 |
05/03/24 |
ASX - By Stock
|
53
|
14K
|
0
|
|
ASX - By Stock
|
RCE |
Re:
Ann: Recce Continues Strategic Partnership with MCRI
|
|
BelowAverage
|
53 |
14K |
0 |
04/03/24 |
04/03/24 |
ASX - By Stock
|
53
|
14K
|
0
|
|
ASX - By Stock
|
GGE |
Re:
Price prediction
|
|
BelowAverage
|
50 |
18K |
3 |
01/03/24 |
01/03/24 |
ASX - By Stock
|
50
|
18K
|
3
|
|
ASX - By Stock
|
GGE |
Re:
Price prediction
|
|
BelowAverage
|
50 |
18K |
1 |
01/03/24 |
01/03/24 |
ASX - By Stock
|
50
|
18K
|
1
|
|
ASX - By Stock
|
GGE |
Price prediction
|
|
BelowAverage
|
50 |
18K |
1 |
01/03/24 |
01/03/24 |
ASX - By Stock
|
50
|
18K
|
1
|
|
ASX - By Stock
|
FHE |
Re:
Ann: DFS Presentation
|
|
BelowAverage
|
17 |
4.8K |
4 |
01/03/24 |
01/03/24 |
ASX - By Stock
|
17
|
4.8K
|
4
|
|
ASX - By Stock
|
FHE |
Re:
Ann: Definitive Feasibility Study Released
|
|
BelowAverage
|
7 |
1.9K |
3 |
28/02/24 |
28/02/24 |
ASX - By Stock
|
7
|
1.9K
|
3
|
|